EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapiesSeptember 24, 2026
General New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patientsBy Healthcare Propulsion StaffSeptember 24, 20260 The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen…
